Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
37.38 USD | +0.56% | -3.86% | +30.33% |
05-09 | Wedbush Raises Price Target on Revolution Medicines to $46 From $42, Maintains Outperform Rating | MT |
05-08 | Revolution Medicines Q1 Net Loss Narrows | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+30.33% | 6.13B | |
+29.03% | 48.16B | |
-0.10% | 41.73B | |
+43.45% | 41.03B | |
-5.26% | 28.77B | |
+11.48% | 25.59B | |
-22.74% | 18.96B | |
+9.06% | 12.92B | |
+30.01% | 12.03B | |
-1.51% | 11.77B |
- Stock Market
- Equities
- RVMD Stock
- News Revolution Medicines, Inc.
- JPMorgan Upgrades Revolution Medicines to Overweight From Neutral, Boosts Price Target to $38 From $32